Clinical Trial Update: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable [Phase 3]

View source ↗

Summary

A Phase 3 long-term study evaluating Baricitinib in combination with topical corticosteroids for adults with moderate-to-severe atopic dermatitis not controlled…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Baricitinib (baricitinib)
• Topical corticosteroids (Corticosteroid)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2021-01-19